INmune Bio (NASDAQ:INMB) Stock Price Down 1.3% - What's Next?Market Beat·Sep 1 at 04:20 AMINMB+7.49%WFC+0.87%
INmune Bio submits EMA orphan drug application for Ebstrocel in RDEBPUBT·Aug 26 at 11:03 AMINMB+7.49%
INmune Bio Q2 2026 Earnings: Tax-Credit Benefit Narrows Net LossTradingKey·Aug 7 at 01:48 AMINMB+7.49%
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical StudyUnusual Whales·Jul 15 at 11:03 AMINMB+7.49%
Strengthening XPro1595 Data and De-Risked Registrational Path Support Buy Rating on INmune Bio with Unchanged $8 Price TargetTip Ranks·Jul 10 at 07:25 PMINMB+7.49%
INmune Bio says Phase 2 XPro trial shows significant Week 24 MRI myelin benefit in early Alzheimer’s patientsPUBT·Jul 9 at 11:00 AMINMB+7.49%
INmune Bio says holders exercise 647,112 warrants at $1.4 per share under inducement offerPUBT·Jul 1 at 11:17 AMINMB+7.49%
